Vascular anomalies: From bedside to bench and back again

Current Problems in Pediatric and Adolescent Health Care

Volumn 32, Issue 3, 2002, Pages 72-93

  Blei, Francine ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOCAPROIC ACID; ANTACID AGENT; BICARBONATE; CORTICOSTEROID; METRONIDAZOLE; ORAPRED; PICIBANIL; PREDNISOLONE; VINCRISTINE;

ANGIOGENESIS; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL BLOOD VESSEL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHINGOID SYNDROME; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE MARKER; DRUG FORMULATION; GASTRITIS; GENE MUTATION; GROWTH RETARDATION; HEMANGIOENDOTHELIOMA; HUMAN; INVOLUTION; KAPOSIFORM HEMANGIOENDOTHELIOMA; LASER SURGERY; LYMPHATIC SYSTEM DISEASE; MYOPATHY; NEUROTOXICITY; SCLEROTHERAPY; SKIN HEMANGIOMA; SPASTICITY; TREATMENT INDICATION; TUMOR LOCALIZATION;

EID: 0036522449     PISSN: 15385442     EISSN: None     Source Type: Journal    
DOI: 10.1067/mps.2002.125533     Document Type: Article

References (164)

1. Rothschild BM, Tanke D, Hershkovitz I, Schultz M. Mesozoic neoplasia: origins of haemangioma in the Jurassic age. Lancet 1998;351:1862.
2. Mulliken J, Young A. Vascular birthmarks: hemangiomas and vascular malformations. WB Saunders Company: Philadelphia, 1988.
3. Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution. J Pediatr 1996; 128:329-35.
4. Nakayama H. Clinical and histological studies of the classification and the natural course of the strawberry mark. J Dermatol 1981;8:277-91.
5. Martinez-Perez D, Fein NA, Boon LM, Mulliken JB. Not all hemangiomas look like strawberries: uncommon presentations of the most common tumor of infancy. Pediatr Dermatol 1995;12:1-6.
6. Boon LM, Fishman SJ, Lund DP, Mulliken JB. Congenital fibrosarcoma masquerading as congenital hemangioma: report of two cases. J Pediatr Surg 1995;30:1378-81.
7. Kasabach H, Merritt K. Capillary hemangioma with extensive purpura. Am J Dis Child 1940;59:1063-70.
8. Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100: 1377-86.
9. Enjolras O, Wassef M, Mazoyer E, Frieden IJ, Rieu PN, Drouet L, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr 1997;130:631-40.
10. Enjolras O, Mulliken JB, Wassef M, Frieden IJ, Rieu PN, Burrows PE, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 2000;42(Pt 1):225-35.
11. Smoller BR, Rosen S. Port-wine stains: a disease of altered neural modulation of blood vessels? Arch Dermatol 1986; 122:177-9.
12. Smoller BR, Kwan TH, Noe JM. Unexpected vascular response to epinephrine in port wine stains. Plast Reconstr Surg 1987;80:784-6.
13. Rosen S, Smoller BR. Port-wine stains: a new hypothesis. J Am Acad Dermatol 1987;17:164-6.
14. Cannistra C, Standoli L. [Viral implication in immature angiomas. Etiopathogenic hypothesis and immunohistopathologic study of eleven cases]. Pathol Biol (Paris) 1994;42:150-5.
15. Horie Y, Kato M. Juvenile hemangioma (infantile hemangioendothelioma) of the parotid gland associated with cytomegalovirus infection. Pathol Int 1999;49:668-71.
16. Smoller BR, Chang PP, Kamel OW. No role for human herpes virus 8 in the etiology of infantile capillary hemangioma. Mod Pathol 1997;10:675-8.
17. Dupin N, Enjolras O, Wassef M, Gorin I, Gradadam M, Huraux M, et al. [Absence of HHV-8 virus detected in immature hemangiomas in infants]. Ann Dermatol Venereol 1998;125:98-9.
18. Ensoli B, Sturzl M, Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv Cancer Res 2001;81:161-200.
19. Burton BK, Schulz CJ, Angle B, Burd LI. An increased incidence of haemangiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn 1995;15:209-14.
20. Reese V, Frieden IJ, Paller AS, Esterly NB, Ferriero D, Levy ML, et al. Association of facial hemangiomas with Dandy-Walker and other posterior fossa malformations. J Pediatr 1993;122:379-84.
21. Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr 1997;131: 643-6.
22. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol 1997;14:173-9.
23. Sasaki GH, Pang CY, Wittliff JL. Pathogenesis and treatment of infant skin strawberry hemangiomas: clinical and in vitro studies of hormonal effects. Plast Reconstr Surg 1984;73: 359-70.
24. Lui W, Zhang S, Hu T, Wei F, Gao Y, Cheng N. Sex hormone receptors of hemangiomas in children. Chin Med J (Engl) 1997;110:349-51.
25. Folkman J. Toward a new understanding of vascular proliferative disease in children. Pediatrics 1984;74:850-6.
26. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91.
27. Kaipainen A, Korhonen J, Pajusola K, Aprelikova O, Persico MG, Terman BI, et al. The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med 1993;178:2077-88.
28. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995;92:3566-70.
29. Boudreau N, Andrews C, Srebrow A, Ravanpay A, Cheresh DA. Induction of the angiogenic phenotype by Hox D3. J Cell Biol 1997;139:257-64.
30. Carmeliet P, Collen D. Vascular development and disorders: moleculars analysis and pathogenic insights. Kidney Int 1998;53:1519-49.
31. Carmeliet P, Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol 1999; 237:133-58.
32. Iljin K, Dube A, Kontusaari S, Korhonen J, Lahtinen I, Oettgen P, et al. Role of ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter. Faseb J 1999;13:377-86.
33. Korpelainen EI, Karkkainen M, Gunji Y, Vikkula M, Alitalo K. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 1999;18:1-8.
34. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, DeMol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83.
35. D'Amore PA. Kissing cousins-evidence for a common vascular cell precursor. Nat Med 2000;6:1323-4.
36. D'Amore PA, Ng YS, Darland DC. Angiogenesis. Science and Medicine 1999;6:44-53.
37. Dube A, Akbarali Y, Sato TN, Libermann TA, Oettgen P. Role of the Ets transcription factors in the regulation of the vascular-specific Tie2 gene. Circ Res 1999;84:1177-85.
38. Breier G. Angiogenesis in embryonic development - a review. Placenta 2000;21(Suppl A):S11-S5.
39. Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci 2000;902: 249-62; discussion 62-4.
40. Gorski DH, Walsh K. The role of homeobox genes in vascular remodeling and angiogenesis. Circ Res 2000;87: 865-72.
41. Hansen-Smith FM. Capillary network patterning during angiogenesis. Clin Exp Pharmacol 2000;27:830-5.
42. Xu Q, Mellitzer G, Wilkinson DG. Roles of Eph receptors and ephrins in segmental patterning. Philos Trans R Soc Lond B Biol Sci 2000;355:993-1002.
43. Gorski DH, Walsh K. Control of vascular cell differentiation by homeiobox transcription factors. Circ Res 2001;88:7-8.
44. Sato Y, Abe M, Tanaka K, Iwasaka C, Oda N, Kanno S, et al. Signal transduction and transcriptional regulation of angiogenesis. Adv Exp Med Biol 2000;476:109-15.
45. Oettgen P. Transcriptional regulation of vascular development. Circ Res 2001;89:380-8.
46. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
47. Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, et al. Universal GFP reporter for the study of vascular development. Genesis 2000;28:75-81.
48. Gunel M, Awad IA, Finberg K, Anson JA, Steinberg GK, Batjer HH, et al. A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans. N Engl J Med 1996;334:946-51.
49. Gunel M, Awad IA, Finberg K, Steinberg GK, Craig HD, Cepeda O, et al. Genetic heterogeneity of inherited cerebral cavernous malformation. Neurosurgery 1996;38:1265-71.
50. Sahoo T, Johnson EW, Thomas JW, Kuehl PM, Jones TL, Dokken CG, et al. Mutations in the gene encoding KRIT1, a Krev-1/rapla binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet 1999;8:2325-33.
51. Laberge-le Couteulx S, Jung HH, Labauge P, Houtteville JP, Lescoat C, Cecillon M, et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 1999;23:189-93.
52. Eerola I, Plate KH, Spiegel R, Boon LM, Mulliken JB, Vikkula M. KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. Hum Mol Genet 2000;9:1351-5.
53. Zhang J, Clatterbuck RE, Rigamonti D, Dietz HC. Mutations in KRIT1 in familial cerebral cavernous malformations. Neurosurgery 2000;46:1272-7; discussion 77-9.
54. Eerola I, McIntyre B, Vikkula M. Identification of eight novel 5′-exons in cerebral capillary malformation gene-1 (CCM1) encoding KRIT1. Biochim Biophys Acta 2001; 1517:464-7.
55. Lucas M, Costa AF, Montori M, Solano F, Zayas MD, lzquierdo G. Germline mutations in the CCM1 gene, encoding Kritl, cause cerebral cavernous malformations. Ann Neurol 2001;49:529-32.
56. Blume-Peytavi U, Adler YD, Geilen CC, Ahmad W, Christiano A, Goerdt S, et al. Multiple familial cutaneous glomangioma: a pedigree of 4 generations and critical analysis of histologic and genetic differences of glomus tumors. J Am Acad Dermatol 2000;42:633-9.
57. Boon LM, Brouillard P, Irrthum A, Karttunen L, Warman ML, Rudolph R, et al. A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21-22. Am J Hum Genet 1999;65:125-33.
58. Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, Barmada MM, et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum Mol Genet 1998;7:2073-8.
59. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 2000;67:295-301.
60. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276:1423-5.
61. Lymbousssaki A, Paranen TA, Olofsson B, Thomas-Crusells J, Fletcher CD, de Waal RM, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol 1998;153:395-403.
62. Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Diamonti AJ, Goumnerov B, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996;87:1181-90.
63. Gil-Nagel A, Dubovsky J, Wilcox KJ, Stewart JM, Anderson VE, Leppik IE, et al. Familial cerebral cavernous angioma: a gene localized to a 15-cM interval on chromosome 7q. Ann Neurol 1996;39:807-10.
64. Notelet L, Chapon F, Khoury S, Vahedi K, Chodkiewicz JP, Courtheoux P, et al. Familial cavernous malformations in a large French kindred: mapping of the gene to the CCM1 locus on chromosome 7q. J Neurol Neurosurg Psychiatry 1997;63:40-5.
65. Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001;107:745-52.
66. Berg JN, Walter JW, Thisanagayam U, Evans M, Blei F, Warier M, et al. Evidence for loss of heterozygosity of 5q in sporadic haemangiomas: are somatic mutations involved in haemangioma formation? J Clin Pathol 2001;54:249-52.
67. Walter J, North P, Waner M, Mizeracki A, Blei F, Walker J, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002;33:295-303.
68. Takahaski K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357-64.
69. Martin-Padura I, DeCastellarnau C, Uccini S, Pilozzi E, Natali PG, Nicotra MR, et al. Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. J Pathol 1995;175:51-7.
70. Berard M, Sordello S, Ortega N, Carrier JL, Peyri N, Wassef M, et al. Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas. Am J Pathol 1997;150:1315-26.
71. Chang J, Most D, Bresnick S, Mehrara B, Steinbrech DS, Reinisch J, et al. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg 1999;103:1-9 discussion 10.
72. Dosanjh A, Chang J, Bresnick S, Zhou L, Reinisch J, Longaker M, et al. In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol 2000;27:441-50.
73. Sunderkotter C, Goebeler M, Schulze-Osthoff K, Bhardwaj R, Sorg C. Macrophage-derived angiogenesis factors. Pharmacol Ther 1991;51:195-216.
74. Isik FF, Rand RP, Gruss JS, Benjamin D, Alpers CE. Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res 1996; 61:71-6.
75. North PE, Waner M, Mizeracki A, Mihm MC Jr. GLUT1: a newly discovered immunohistochemical marker for juvenille hemangiomas. Hum Pathol 2000;31:11-22.
76. North PE, Waner M, Mizeracki A, Mrak RE, Nicholas R, Kincannon J, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001;137:559-70.
77. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000;343:185-9.
78. Kraling BM, Razon MJ, Boon LM, Zurakowski D, Seachord C, Darveau RP, et al. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 1996; 148:1181-91.
79. Jang YC, Arumugam S, Ferguson M, Gibran NS, Isik FF. Changes in matrix composition during the growth and regression of human hemangiomas. J Surg Res 1998;80:91-5.
80. Jang YC, Isik FF, Gibran NS. Nerve distribution in hemangiomas depends on the proliferative state of the microvasculature. J Surg Res 2000;93:144-8.
81. Mancini AJ, Smoller BR. Proliferation and apoptosis within juvenile capillary hemangiomas. Am J Dermatopathol 1996; 18:505-14.
82. Hasan Q, Ruger BM, Tan ST, Gush J, Davis PF. Clusterin/apoJ expression during the development of hemangioma. Hum Pathol 2000;31:691-7.
83. Teruyama K, Abe M, Nakano T, Iwasaka-Yagi C, Takahashi S, Yamada S, et al. Role of transcription factor Ets-1 in the apoptosis of human vascular endothelial cells. J Cell Physiol 2001;188:243-52.
84. Bree AF, Siegfried E, Sotelo-Avila C, Nahass G. Infantile hemangiomas: speculation on placental trophoblastic origin. Arch Dermatol 2001;137:573-7.
85. Burns AJ, Kaplan LC, Mulliken JB. Is there an association between hemangioma and syndromes with dysmorphic features? Pediatrics 1991;88:1257-67.
86. Ertem D, Acar Y, Kotiloglu E, Yucelten D, Pehlivanoglu E. Blue rubber bleb nevus syndrome. Pediatrics 2001;107:418-20.
87. Moodley M, Ramdial P. Blue rubber bleb nevus syndrome: case report and review of the literature. Pediatrics 1993;92: 160-2.
88. Boente MD, Cordisco MR, Frontini MD, Asial RA. Blue rubber bleb nevus (Bean syndrome): evolution of four cases and clinical response to pharmacologic agents. Pediatr Dermatol 1999;16:222-7.
89. Davidson TI, Kissin MW, Bradish CF, Westbury G. Angiosarcoma arising in a patient with Maffucci syndrome. Eur J Surg Oncol 1985; 11:381-4.
90. Sun TC, Swee RG, Shives TC, Unni KK. Chondrosarcoma in Maffucci's syndrome. J Bone Joint Surg Am 1985;67: 1214-9.
91. Ben-Itzhak I, Denolf FA, Versfeld GA, Noll BJ. The Maffucci syndrome. J Pediatr Orthop 1988;8:345-8.
92. Hisaoka M, Aoki T, Kuoho H, Chosa H, Hashimoto H. Maffucci's syndrome associated with spindle cell hemangioendothelioma. Skeletal Radiol 1997;26:191-4.
93. Berg JN, Guttmacher AE, Marchuk DA, Porteous ME. Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? J Med Genet 1996;33:256-7.
94. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189-95.
95. Blei F, Karp N, Rofsky N, Rosen R, Greco MA. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: case report and review of the literature. Pediatr Hematol Oncol 1998;15: 295-305.
96. Maria BL, Neufeld JA, Rosainz LC, Drane WE, Quisling RG, Ben-David K, et al. Central nervous system structure and function in Sturge-Weber syndrome: evidence of neurologic and radiologic progression. J Child Neurol 1998;13: 606-18.
97. Dyken PR. Sturge-Weber disease: facial features of pediatric neurologic syndromes. J Child Neurol 1999;14:82.
98. Enjolras O, Riche MC, Merland JJ. Facial port-wine stains and Sturge-Weber syndrome. Pediatrics 1985;76:48-51.
99. Tallman B, Tan OT, Tallman B, Tan OT, Morelli JG, Piepenbrink J, Stafford TJ, Trainor S, et al. Location of port-wine stains and the likelihood of ophthalmic and/or central nervous system complications. Pediatrics 1991;87: 323-7.
100. Ezekowitz RA. The relationship between facial and airway hemangiomas: does seeing red bode ill? J Pediatr 1997;131: 514-5.
101. Sie KC, McGill T, Healy GB. Subglottic hemangioma: ten years' experience with the carbon dioxide laser. Ann Otol Rhinol Laryngol 1994;103:167-72.
102. Ohlms LA, Jones DT, McGill TJ, Healy GB. Interferon α-2a therapy for airway hemangiomas. Ann Otol Rhinol Laryngol 1994;103:1-8.
103. Hoeve LJ, Kuppers GL, Verwoerd CD. Management of infantile subglottic hemangioma: laser vaporization, submucous resection, intubation, or intralesional steroids? Int J Pediatr Otorhinolaryngol 1997;42:179-86.
104. Kacker A, April M, Ward RF. Use of potassium titanyl phosphate (KTP) laser in management of subglottic hemangiomas. Int J Pediatr Otorhinolaryngol 2001;59:15-21.
105. Deleted by author.
106. Bilyk JR, Adamis AP, Mulliken JB. Treatment options for periorbital hemangioma of infancy. Int Ophthalmol Clin 1992;32:95-109.
107. Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus 1994;31: 153-6.
108. Cruz OA, Zarnegar SR, Myers SE. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology 1995;102:2012-5.
109. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986;17:229-31.
110. Yap EY, Bartley GB, Hohberger GG. Periocular capillary hemangioma: a review for pediatricians and family physicians. Mayo Clin Proc 1998;73:753-9.
111. Frieden IJ, Reese V, Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996;132: 307-11.
112. Metry DW, Dowd CF, Barkovich Al, Frieden IJ. The many faces of PHACE syndrome. J Pediatr 2001;139:117-23.
113. Burrows PE, Robertson RL, Mulliken JB, Beardsley DS, Chaloupka JC, Ezekowitz RA, et al. Cerebral vasculopathy and neurologic sequelae in infants with cervicofacial hemangioma: report of eight patients. Radiology 1998;207: 601-7.
114. Coats DK, Paysse EA, Levy ML. PHACE: a neurocutaneous syndrome with important ophthalmologic implications: a case report and literature review. Ophthalmology 1999;106: 1739-41.
115. Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001;44:962-72.
116. Mallory SB, Morris P. Bleeding hemangioma detected by enuresis blanket. Pediatr Dermatol 1989;6:139-40.
117. Blei F, Chianese J, Kauvar A, Karp N. Topical amicar and gelfoam as adjunctive therapies for bleeding hemangiomas. Int Pediatr 1999;14:168-70.
118. Miller S, Smith R, Shochat S. Compression treatment of hemangiomas. Plast Reconstr Surg 1976;58:573-79.
119. Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. Pediatrics 1989;83:977-80.
120. Laurent I, Leaute-Labreze C, Maleville J, Taieb A. [Faun tail and sacral hemangioma associated with occult spinal dysraphism]. Ann Dermatol Venereol 1998;125:414-6.
121. Goldberg NS, Hebert AA, Esterly NB. Sacral hemangiomas and multiple congenital abnormalities. Arch Dermatol 1986; 122:684-7.
122. Shian WJ, Chi CS, Wong TT. Lipomyelomeningocele: a 9-year review. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1994;35:57-62.
123. Haik BG, Clancy P, Ellsworth RM, Perina A, Zimmerman K. Ocular manifestations in diffuse neonatal hemangiomatosis. J Pediatr Ophthalmol Strabismus 1983;20:101-5.
124. Stillman AE, Hansen RC, Hallinan V, Strobel C. Diffuse neonatal hemangiomatosis with severe gastrointestinal involvement. Favorable response to steroid therapy. Clin Pediatr (Phila) 1983;22:589-91.
125. Held JL, Haber RS, Silvers DN, Grossman ME. Benign neonatal hemangiomatosis: review and description of a patient with unusually persistent lesions. Pediatr Dermatol 1990;7:63-6.
126. Boon LM, Burrows PE, Paltiel HJ, Lund DP, Ezekowitz RA, Folkman J, et al. Hepatic vascular anomalies in infancy: a twenty-seven-year experience. J Pediatr 1996;129:346-54.
127. Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997;37:631-7.
128. Dieterich-Miller CA, Safford PL. Psychosocial development of children with hemangiomas: home, school, health care collaboration. Child Health Care 1992;21:84-9.
129. Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics 1998;101(Pt 1):446-52.
130. Kunkel EJ, Zager RP, Hausman CL, Rabinowitz LG. An interdisciplinary group for parents of children with hemangiomas. Psychosomatics 1994;35:524-32.
131. Schwager K, Waner M, Hohmann D. Hemangioma: differential diagnosis and necessary early laser treatment. Adv Otorhinolaryngol 1995;49:70-4.
132. Eichenfield LF. Vascular lesion laser: practical techniques or some "light" suggestions. Pediatr Dermatol 1999;16:332-4.
133. Achauer BM, Celikoz B, VanderKam VM. Intralesional bare fiber laser treatment of hemangioma of infancy. Plast Reconstr Surg 1998; 101: 1212-7.
134. Burstein FD, Simms C, Cohen SR, Williams JK, Paschal M. Intralesional laser therapy of extensive hemangiomas in 100 consecutive pediatric patients. Ann Plast Surg 2000;44:188-94.
135. Brown SH, Neerhout RC, Fonkalsrud EW. Prednisone therapy in the management of large hemangiomas in infants and children. Surgery 1972;71:168-73.
136. Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr 1968;72:351-7.
137. Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993;155:568-78.
138. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 1994;55:419-34.
139. Sumino H, Nakamura T, Ichikawa S, Kanda T, Sakamaki T, Sato K, et al. Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia. Atherosclerosis 2000;148:189-95.
140. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics 2000;105(Pt 1): 117-20.
141. Blei F, Chianese J. Corticosteroid toxicity in infants treated for endangering hemangiomas: experience and guidelines for monitoring. Int Pediatr 1999;14:146-53.
142. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104:1616-23.
143. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon α-2a. N Engl J Med 1989;320:1197-200.
144. Ezekowitz A, Mulliken J, Folkman J. Interferon alpha therapy of haemangiomas in newborns and infants. Br J Haematol 1991;79(Suppl 1):67-8.
145. Ezekowitz RA, Mulliken JB, Folkman J. Interferon α-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63.
146. Ezekowitz A, Mulliken J, Folkman J. Additional corrections: interferon for hemangiomas of infancy. N Engl J Med 1995;333:595-6.
147. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997; 19: 237-44.
148. Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, MacDonald D, Folkman J, et al. Spastic diplegia as a complication of interferon α-2a treatment of hemangiomas of infancy. J Pediatr 1998;132(Pt 1):527-30.
149. Egbert JE, Nelson SC. Neurologic toxicity associated with interferon alfa treatment of capillary hemangioma. J AAPOS 1997;1:190.
150. Enjolras O. Neurotoxicity of interferon alfa in children treated for hemangiomas. J Am Acad Dermatol 1998;39: 1037-8.
151. Dubois J, Hershon L, Carmant L, Belanger S, Leclerc JM, David M. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr 1999;135:782-5.
152. Blei F, Isakof M, Deb G. The response of parotid hemangiomas to the use of systemic interferon alfa-2a or corticosteroids. Arch Otolaryngol Head Neck Surg 1997;123:841-4.
153. Zide BM, Glat PM, Stile FL, Longaker MT. Vascular lip enlargement: Part I. Hemangiomas-tenets of therapy. Plast Reconstr Surg 1997; 100: 1664-73.
154. Zide BM, Glat PM, Stile FL, Longaker MT. Vascular lip enlargement: Part II. Port-wine macrocheilia-tenets of therapy based on normative values. Plast Reconstr Surg 1997; 100:1674-81.
155. Berenguer B, Burrows PE, Zurakowski D, Mulliken JB. Sclerotherapy of craniofacial venous malformations: complications and results. Plast Reconstr Surg 1999;104:1-11; discussion 12-5.
156. Foldi E. Treatment of lymphedema and patient rehabilitation. Anticancer Res 1998; 18(3C):2211-2.
157. Foldi E, Sauerwald A, Hennig B. Effect of complex decongestive physiotherapy on gene expression for the inflammatory response in peripheral lymphedema. Lymphology 2000; 33:19-23.
158. Greinwald JH Jr, Burke DK, Sato Y, Poust RI, Kimura K, Bauman NM, et al. Treatment of lymphangiomas in children: an update of Picibanil (OK-432) sclerotherapy. Otolaryngol Head Neck Surg 1999;121:381-7.
159. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
160. Folkman J. Angiogenesis research: from laboratory to clinic. Forum (Genova) 1999;9(Suppl 3):59-62.
161. Vincent P, Plauchu H, Hazan J, Faure S, Weissenbach J, Gaudet J. A third locus for hereditary hemorrhagic telangiectasia maps to chromosome 12q. Hum Mol Genet 1995;4: 945-50.
162. Calvert JT, Riney TJ, Kontos CD, Cha EH, Prieto VG, Shea CR, et al. Allelic and locus heterogeneity in inherited venous malformations. Hum Mol Genet 1999;8:1279-89.
163. Gallione CJ, Pasyk KA, Boon LM, Lennon F, Johnson DW, Helmbold EA, et al. A gene for familial venous malformations maps to chromosome 9p in a second large kindred. J Med Genet 1995;32:197-99.
164. Walter JW, Blei F, Anderson JL, Orlow SJ, Speer MC, Marchuk DA. Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet 1999;82:77-83.